Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy

European Journal of Cancer Part A

Volumn 33, Issue 9, 1997, Pages 1393-1399

  Berger, T ^a,b   Malayeri, R ^a   Doppelbauer, A ^a   Krajnik, G ^a   Huber, H ^a   Auff, E ^a   Pirker, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Chemotherapy; Cisplatin; Monitoring; Neurotoxicity; Paclitaxel; Peripheral neuropathy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PERONEUS NERVE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; VIBRATION;

EID: 0030804578     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00103-2     Document Type: Article

References (22)

1. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989, 111, 273-279.
2. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Nail Cancer Inst 1990, 82, 1247-1259.
3. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). NEJM 1995, 332, 1004-1014.
4. Sarosy G, Kohn E, Stone DA, et al. Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992, 10, 1165-1170.
5. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with Paclitaxel (Taxol). Semin Oncol (Suppl 3) 1993, 20, 1-15.
6. Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of Paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993, 11, 2010-2020.
7. van Gerven JMA, Moll JWB, van den Bent MJ, et al. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994, 30A, 1074-1077.
8. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989, 39, 368-373.
9. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from Taxol and cisplatin chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994, 35, 304-311.
10. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. NEJM 1996, 334, 1-6.
11. Pirker R, Krajnik G, Zöchbauer S, Malayeri R, Kneussl M, Huber H. Paclitaxel/cisplatin in advanced non-small-cell lung cancer. Ann Oncol 1995, 6, 833-835.
12. Roelofs RJ, Hrubesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984, 3, 934-938.
13. Sahenk Z, Barohn R, New P, Mendell JR. Taxol neuropathy. Arch Neurol 1994, 51, 726-729.
14. Cavalletti G, Bogliun G, Marzorati L, et al. Peripheral neurotoxicity of Taxol in patients previously treated with cisplatin. Cancer 1995, 75, 1141-1150.
15. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994, 12, 2654-2666.
16. DiPaola R, Rodriguez R, Reclo A, et al. Phase I study of amifostine (AMI) and granulocyte colony stimulating factor (G-CSF) with escalating doses of paclitaxel (TAX) in patients with advanced malignancies. Ann Oncol (Suppl 5) 1996, 7, 132.
17. Peterson ER, Crain SM. Nerve growth factor attenuates neurotoxic effects of taxol on spinal cord-ganglion explants from fetal mice. Science 1982, 217, 377-379.
18. Apfel SC, Arezzo JC, Lipton LA, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992, 31, 76-80.
19. Hol EM, Mandys V, Sodaar P, Gispen WH, Bar PR. Protection by an ACTH 4-9 analogue against the toxic effects of cisplatin and taxol on sensory neurons and glial cells in vitro. J Neurosci Res 1994, 39, 178-185.
20. Drago J, Kilpatrick TJ, Koblar SA, Talman PS. Growth factors: potential therapeutic applications in neurology. J Neurol Neurosurg Psych 1994, 57, 1445-1450.
21. Dittrich C, Zifko U, Fazeny B, Fiegl M, Grisold W, Huber H. Vinorelbine after paclitaxel in breast cancer: Cross resistance and cumulative neurotoxicity? Ann Oncol 1994, 5, 473-474.
22. Parimoo D, Jeffers S, Muggia FM. Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst 1996, 88, 1079-1080.